Show simple item record

dc.contributor.authorPettas, Efstathios
dc.contributor.authorSavva, Vasiliki
dc.contributor.authorTheofilou, Vasileios Ionas
dc.contributor.authorGeorgaki, Maria
dc.contributor.authorNikitakis, Nikolaos G.
dc.date.accessioned2022-01-19T16:41:08Z
dc.date.available2022-01-19T16:41:08Z
dc.date.issued2022-01-01
dc.identifier.urihttp://hdl.handle.net/10713/17632
dc.description.abstractAn intact and fully functional immune system plays a crucial role in the prevention of several infectious diseases. Interleukin (IL)17 is significantly involved in oral mucosa immunity against several antigens and microorganisms, including Candida albicans (CA). Herein, we present three cases of oral candidiasis (OC) related to the use of an IL17A inhibitor for psoriasis. Three psoriatic individuals presented for evaluation of widespread symptomatic oral lesions temporally correlated with the onset of IL17A inhibitors (secukinumab in two patients and brodalumab in one patient). Clinical examination revealed either partially removable white plaques in an erythematous background (case #1) or diffuse erythematous lesions (cases #2 and 3) involving several areas of the oral mucosa. Cytology smear, accompanied by histopathologic examination in case #1, confirmed the clinical impression of OC in all three cases. All patients received antifungal therapy with satisfactory clinical response. No discontinuation of the antipsoriatic regimen was recommended, but all patients were advised to remain under monitoring for possible OC relapses. During the last few years, new systemic biologic agents targeting IL17 have been used for the management of variable immunemediated diseases. Few clinical trials and scarce case reports have shown that these medications place individuals at high risk of developing candidiasis. We propose that patients treated with these medications should be at close monitoring for the development of OC and, if it occurs, receive appropriate management. © 2021 by the authors.en_US
dc.description.urihttps://doi.org/10.3390/diagnostics12010003en_US
dc.language.isoenen_US
dc.publisherMDPI AGen_US
dc.relation.ispartofDiagnostics (Basel, Switzerland)en_US
dc.subjectBrodalumaben_US
dc.subjectInhibitoren_US
dc.subjectInterleukin 17en_US
dc.subjectOral candidiasisen_US
dc.subjectPsoriasisen_US
dc.subjectSecukinumaben_US
dc.subjectType 17 immunityen_US
dc.titleOral Candida Infection in Psoriatic Patients Treated with IL17A Inhibitors: Report of 3 Cases and a Comprehensive Review of the Literatureen_US
dc.typeArticleen_US
dc.identifier.doi10.3390/diagnostics12010003
dc.source.journaltitleDiagnostics
dc.source.volume12
dc.source.issue1


This item appears in the following Collection(s)

Show simple item record